Is LPTN a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

499 people get LPTN articles and Market Currents by email alert.

Get email alerts on LPTN »

HEADLINES:

Lpath: The Leader In Lipidomics
Bay Area Biotech • Thu, May 2
Lpath Adds Two Key Members to its Executive Team

GlobeNewswire (Apr 16, 2013)
Lpath Granted Key European and U.S. Patents Related to Anti-Cancer Drug Program, ASONEP

Marketwire (Mar 22, 2013)
Lpath to Present at ROTH Capital Partners 25th Annual Growth Stock Conference on March 19, 2013

Marketwire (Mar 12, 2013)
Lpath Signs Collaboration and License Agreement With Provista Diagnostics to Develop Cancer Diagnostics

Marketwire (Mar 6, 2013)
Lpath to Present Data at Arrowhead's 3rd Annual Traumatic Brain Injury Conference on March 7, 2013

Marketwire (Feb 25, 2013)
Lpath Promotes Leigh Hsu, Ph.D., to Vice President of Corporate Development

Marketwire (Feb 13, 2013)
What Other Neuropathic Pain Drugs Are Missing
Cris Frangold • Sun, Feb 3 • 11 Comments
Age-Related Macular Degeneration: A Promising Investment Opportunity
Cris Frangold • Mon, Jan 21 • 4 Comments
Lpath Sets Investor Update Conference Call for Thursday, January 3, 2013 at 4:30 p.m. ET

Marketwire (Dec 26, 2012)
Recent Small Pharma Offerings Create Tempting Current Entries
Chemistfrog • Fri, Dec 21, 2012 • 2 Comments
Lpath Announces Pricing of Public Offering of Common Stock

Marketwire (Dec 14, 2012)
Lpath Announces Proposed Public Offering of Common Stock

Marketwire (Dec 13, 2012)
Weekly Stock Watch, Week Of 10 December, 2012
VFC's Stock House • Mon, Dec 10, 2012 • 1 Comment
Lpath Granted Key European Patent Related to iSONEP Drug Program

Marketwire (Dec 5, 2012)
Weekly Stock Watch: Week Of 3 December
VFC's Stock House • Tue, Dec 4, 2012 • 3 Comments
Lpath Ranks Eighth Fastest Growing Biotechnology Company and 60th Overall Among N. America's Fastest Growing Companies in Deloitte's 2012 Technology Fast 500

Marketwire (Dec 3, 2012)
Lpath's Q3 Filing Shines The Way For A Catalyst Filled 2013
Chemistfrog • Fri, Nov 30, 2012 • 6 Comments
Stock Watch Thursday, 15 November
VFC's Stock House • Thu, Nov 15, 2012
Current Prime Pharma Entries In Anticipation Of Prime Time Exits
Chemistfrog • Tue, Nov 6, 2012

To learn more about Seeking Alpha Pro, click here.

Lpath: The Leader In Lipidomics
Bay Area Biotech • Thu, May 2
What Other Neuropathic Pain Drugs Are Missing
Cris Frangold • Sun, Feb 3 • 11 Comments
Lpath's Q3 Filing Shines The Way For A Catalyst Filled 2013
Chemistfrog • Fri, Nov 30, 2012 • 6 Comments
Lpathomab Offers Hope In Billion-Dollar Neurotrauma And Pain Markets
LastFinancier • Mon, Oct 22, 2012 • 3 Comments
Lpath Restarts NEXUS Trial; Breathes New Life Into Shares
Brian L. Wilson • Wed, Oct 10, 2012 • 2 Comments
Why Lpath Shares Could Soar Ahead Of ISONEP Trial
LastFinancier • Fri, Jul 27, 2012 • 7 Comments
Lpath Back In Play
Brian L. Wilson • Tue, May 15, 2012 • 1 Comment
Lpath: A Solid Pipeline With Good PPS
Dan Lukehart • Thu, Apr 5, 2012 • 2 Comments
Lpath: With Share Offering Done, Now Is The Time To Buy
Dan Lukehart • Wed, Mar 7, 2012 • 3 Comments
Why Morgan Joseph Expects Triple-Digit Gains For This Pfizer Partner
Takeover Analyst • Mon, Mar 5, 2012 • 3 Comments
Lpath Dip May Be Simply A Buying Opportunity
VFC's Stock House • Wed, Feb 29, 2012 • 2 Comments
LPath's Form / Fill Delay Disappoints Investors: Long-Term Buying Opportunity?
Steven Breazzano • Thu, Feb 2, 2012 • 10 Comments
One Amazing Pharmaceutical Stock To Watch In 2012
Brian L. Wilson • Wed, Dec 28, 2011 • 1 Comment
Lpath Is Many Years Ahead Of The Competition
ScriptVolume • Wed, Dec 7, 2011
LPath Investors Have iSONEP Trial Results In Sight
Steven Breazzano • Wed, Nov 2, 2011 • 3 Comments
LPath, Inc.: Multiple Phase 2 Trials and Pfizer Partnership Provide Path to Profits
Steven Breazzano • Tue, Feb 22, 2011

Age-Related Macular Degeneration: A Promising Investment Opportunity
Cris Frangold • Mon, Jan 21 • 4 Comments
Recent Small Pharma Offerings Create Tempting Current Entries
Chemistfrog • Fri, Dec 21, 2012 • 2 Comments
Weekly Stock Watch, Week Of 10 December, 2012
VFC's Stock House • Mon, Dec 10, 2012 • 1 Comment
Weekly Stock Watch: Week Of 3 December
VFC's Stock House • Tue, Dec 4, 2012 • 3 Comments
Stock Watch Thursday, 15 November
VFC's Stock House • Thu, Nov 15, 2012
Current Prime Pharma Entries In Anticipation Of Prime Time Exits
Chemistfrog • Tue, Nov 6, 2012
Weekly Stock Watch, Week Of November 5
VFC's Stock House • Mon, Nov 5, 2012 • 5 Comments
Weekly Stock Watch, Week Of 29 October
VFC's Stock House • Mon, Oct 29, 2012 • 4 Comments
New Developments In Lipids To Watch Closely
Cris Frangold • Sat, Oct 27, 2012
Weekly Stock Watch: Week Of 4 September
VFC's Stock House • Tue, Sep 4, 2012 • 6 Comments
Weekly Stock Watch For August 20
VFC's Stock House • Mon, Aug 20, 2012 • 4 Comments
Weekly Stock Watch, Week Of August 6
VFC's Stock House • Sun, Aug 5, 2012 • 4 Comments
Weekly Stock Watch, Week Of July 23
VFC's Stock House • Mon, Jul 23, 2012 • 1 Comment
Sunshine Heart's Pullback Offers Investors A Second Chance
VFC's Stock House • Wed, Jul 18, 2012 • 5 Comments
Big Week For Healthcare: Stocks To Watch
VFC's Stock House • Tue, Jul 17, 2012 • 3 Comments
Weekly Stock Watch: Week Of July 9
VFC's Stock House • Sun, Jul 8, 2012
Weekly Stock Watch, Week Of July 1
VFC's Stock House • Mon, Jul 2, 2012
Bio Pharma Movers List: Wednesday June 20
Scott Matusow • Wed, Jun 20, 2012 • 83 Comments
Flush With Fresh Cash, Pfizer Could Be Ready To Realize Some Speculative Moves
VFC's Stock House • Tue, Apr 24, 2012 • 1 Comment
NovaBay Pharmaceuticals May Be Highly Undervalued, Based On Pending Catalysts, Market Potential
VFC's Stock House • Thu, Mar 22, 2012

There are no Transcripts on LPTN.

Lpath Adds Two Key Members to its Executive Team

GlobeNewswire (Apr 16, 2013)
Lpath Granted Key European and U.S. Patents Related to Anti-Cancer Drug Program, ASONEP

Marketwire (Mar 22, 2013)
Lpath to Present at ROTH Capital Partners 25th Annual Growth Stock Conference on March 19, 2013

Marketwire (Mar 12, 2013)
Lpath Signs Collaboration and License Agreement With Provista Diagnostics to Develop Cancer Diagnostics

Marketwire (Mar 6, 2013)
Lpath to Present Data at Arrowhead's 3rd Annual Traumatic Brain Injury Conference on March 7, 2013

Marketwire (Feb 25, 2013)
Lpath Promotes Leigh Hsu, Ph.D., to Vice President of Corporate Development

Marketwire (Feb 13, 2013)
Lpath Sets Investor Update Conference Call for Thursday, January 3, 2013 at 4:30 p.m. ET

Marketwire (Dec 26, 2012)
Lpath Announces Pricing of Public Offering of Common Stock

Marketwire (Dec 14, 2012)
Lpath Announces Proposed Public Offering of Common Stock

Marketwire (Dec 13, 2012)
Lpath Granted Key European Patent Related to iSONEP Drug Program

Marketwire (Dec 5, 2012)
Lpath Ranks Eighth Fastest Growing Biotechnology Company and 60th Overall Among N. America's Fastest Growing Companies in Deloitte's 2012 Technology Fast 500

Marketwire (Dec 3, 2012)
Lpath Announces Filing of Shelf Registration Statement

Marketwire (Nov 2, 2012)

LPTN vs. ETF Alternatives

Company Description

We are a biotechnology company focused on the discovery and development of lipidomic-based therapeutic antibodies, an emerging field of medical science that targets bioactive signaling lipids to treat a wide range of human diseases. We have two product candidates that are currently in clinical... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Friday, December 14, 2012, 3:29 PM Lpath (LPTN -19.5%) tanks today after announcing a public offering for an undisclosed ammount of shares. Terms weren't disclosed, and the offering is subject to customary market conditions with no assurances as to whether or when it may be complete. Summer Street Research Partners is sole book-running manager for the offering. Comment! [Healthcare, On the Move]
Friday, December 14, 2012, 12:45 PM Midday top 10 gainers: ALIM +30%. STXS +19%. QUAD +18%. RIGL +15%. CHOP +19%. OTT +16%. ZAZA +13%. ALU +12%. AXR +11%. SZYM +11%.
Midday top 10 Losers: YOD -23%. LPTN -18%. CYTX -15%. ZQK -15%. BBY -15%. USNA -11%. PAY -10%. MEIP -9%. LAS -9%. VGZ -10%. Comment!
Monday, August 27, 2012, 9:31 AM The FDA lifts a clinical hold on Lpath's (LPTN.OB) iSONEP, an antibody the firm is developing to treat wet AMD and possibly other eye disorders. The FDA placed the hold in January after finding that a contractor was not complying with its regulations, but Lpath has since replaced the supplier. (PR) Comment! [Healthcare]
Monday, July 30, 2012, 9:38 AM Lpath's (LPTN.OB) Lpathomab treatment performed well in tests on mice with partially severed spinal cords. Lpath says Lpathomab "reverses much of the damage caused by trauma to the nervous system," bringing scientists closer to finding a treatment for spinal cord injury. The results of the study have been published in the American Journal of Pathology. (PR) Comment! [Healthcare]
Friday, January 27, 2012, 10:12 AM Shares of Lpath (LPTN.OB -31.8%) plummet after the biotech company temporarily suspends trials for its PEDigree and Nexus lipidomics-based antibody therapeutics. LPTN says it took the action when it learned its fill/finish contractor was not in FDA compliance for manufacturing requirements. (submitted by M.E. Garza) Comment! [Healthcare, On the Move]

LPTN Lpath Inc.

LPTN

Lpath Inc.